[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cel-Sci Corp (CVM)

Cel-Sci Corp (CVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,060
  • Shares Outstanding, K 8,493
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,410 K
  • EBIT $ -22 M
  • EBITDA $ -18 M
  • 60-Month Beta 0.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-2.70
  • Growth Rate Est. (year over year) +37,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8900 +59.55%
on 05/12/26
3.3999 -58.23%
on 04/23/26
-1.9200 (-57.49%)
since 04/22/26
3-Month
0.8900 +59.55%
on 05/12/26
4.9500 -71.31%
on 04/17/26
-3.3800 (-70.42%)
since 02/20/26
52-Week
0.8900 +59.55%
on 05/12/26
13.4768 -89.46%
on 08/27/25
-1.0400 (-42.28%)
since 05/22/25

Most Recent Stories

More News
CEL-SCI Reports Fiscal Second Quarter 2026 Results

On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026 Signed Key Partnership with Amarox to Advance Multikine...

CVM : 1.4200 (-2.07%)
CEL-SCI Announces Closing of Public Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts public offering of 6,000,000...

CVM : 1.4200 (-2.07%)
CEL-SCI Corporation Announces Pricing of Public Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000...

CVM : 1.4200 (-2.07%)
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia

50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation  ...

CVM : 1.4200 (-2.07%)
CEL-SCI Reports Fiscal First Quarter 2026 Results

Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study Entering Saudi Oncology Market, Potentially...

CVM : 1.4200 (-2.07%)
CEL-SCI Reports Fiscal 2025 Results

Filed for Breakthrough Designation for Multikine in Saudi Arabia A 212-patient Confirmatory Registration Study for Multikine in...

CVM : 1.4200 (-2.07%)
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executive...

CVM : 1.4200 (-2.07%)
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Vienna, Virginia--(Newsfile Corp. - October 10, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Officer,...

CVM : 1.4200 (-2.07%)
CEL-SCI Announces Closing of $10 Million Public Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its offering of 1,111,200 shares of its common...

CVM : 1.4200 (-2.07%)
CEL-SCI Announces Pricing of $10 Million Public Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200...

CVM : 1.4200 (-2.07%)

Business Summary

CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins,...

See More

Key Turning Points

3rd Resistance Point 1.5867
2nd Resistance Point 1.5333
1st Resistance Point 1.4767
Last Price 1.4200
1st Support Level 1.3667
2nd Support Level 1.3133
3rd Support Level 1.2567

See More

52-Week High 13.4768
Fibonacci 61.8% 8.6686
Fibonacci 50% 7.1834
Fibonacci 38.2% 5.6982
Last Price 1.4200
52-Week Low 0.8900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.